Author

Isabella Temelkoska

Children's Cancer Institute Australia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Alvin KamiliiD· 1 shared Andrew J. GiffordiD· 1 shared Angela LiniD· 1 shared Brandon A. HearniD· 1 shared Caroline J. AtkinsoniD· 1 shared Chelsea MayohiD· 1 shared Christina H.T. Bui· 1 shared Greg M. ArndtiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alvin KamiliORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma

Alvin Kamili, Brandon A. Hearn, Isabella Temelkoska, Joan Solomon, Madeleine S. Wheatley, Christina H.T. Bui, Caroline J. Atkinson, Leith-Justin Elhassadi, Sadia Qureshi, Jayne E. Murray, Roxanne Cadiz, Andrew J. Gifford, Lujing Cui, Lewis Crowley, Angela Lin, , Jamie I. Fletcher

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

bioRxiv · Sep 10, 2026 · PreprintCancer Biology